Urology news for Sunday, November 1, 2026

Top 5 in urology

• PROTEUS substudy: perioperative apalutamide plus ADT improves event-free survival before RP RCT · Eur Urol · 2026-11-01

  In a randomized substudy of high-risk localized/locally advanced prostate cancer patients undergoing radical prostatectomy, adding 1-year perioperative apalutamide plus ADT improved event-free survival versus surgery alone (median not reached vs 19.1 months; 3-year EFS 63% vs 41%).

  Why it matters: Supports a perioperative intensification strategy with apalutamide plus ADT around surgery in high-risk localized disease.

  More Prostate cancer news
• Combining PSMA PET with MRI improves focal therapy eligibility detection versus either alone Retrospective · J Nucl Med · 2026-10-30

  In 112 men validated against whole-mount prostatectomy specimens, combining PSMA PET/CT and MRI increased sensitivity to detect true ineligibility for focal therapy to 83% compared with each test alone, but specificity fell to 26%, meaning more eligible patients would be incorrectly excluded.

  Why it matters: Suggests dual imaging could better flag disease extent unsuitable for focal therapy, but the trade-off is many false positives that would exclude otherwise appropriate candidates.

  More Prostate cancer news
• Meta-analysis: urethroplasty for post-BPH surgery bulbomembranous strictures shows 90% pooled patency Meta-analysis · BJU Int · 2026-11-01

  A systematic review and meta-analysis of 417 patients from 9 observational studies found an overall pooled patency rate of 90% for urethroplasty after bulbomembranous strictures following BPH surgery, with patency around 87-94% depending on technique, though definitions of patency and continence varied widely.

  Why it matters: Provides pooled benchmark patency rates for a challenging post-BPH stricture population, though heterogeneous outcome definitions and moderate-to-serious risk of bias limit certainty.

  More Reconstruction and trauma news
• Combined nodal status and lymphovascular invasion refine risk stratification after radical cystectomy Retrospective · Eur Urol Focus · 2026-10-30

  In a multicenter cohort of 1,229 patients after upfront radical cystectomy, lymphovascular invasion was independently associated with worse disease-specific survival in both node-negative and node-positive disease, creating three prognostic groups with 5-year disease-specific survival of 65%, 48%, and 25%.

  Why it matters: Raises the question of whether lymphovascular invasion status could help refine postoperative counseling and adjuvant therapy discussions, pending prospective validation.

  More Bladder cancer news
• SEER analysis estimates years of life lost by local treatment in intermediate-risk prostate cancer Retrospective · World J Urol · 2026-10-31

  In a SEER cohort of 220,113 men with intermediate-risk prostate cancer, years of life lost after radical prostatectomy or radiotherapy were compared with population controls; untreated men showed a 0.21-year disadvantage overall, worsening in younger or unfavorable-risk subgroups.

  Why it matters: Hypothesis generating only. Results differ by age and treatment subgroup, so read the abstract before drawing conclusions about radical prostatectomy versus radiotherapy; SEER cannot capture comorbidity, treatment selection or quality of life.

  More Prostate cancer news

Prostate cancer news

• 4Kscore as reflex test could cut MRI referrals 71% in men with PSA 1.8-2.99 Prospective · Eur Urol Open Sci · 2026-10-31

  Among 555 men from the Göteborg-2 screening trial with PSA 1.80-2.99 ng/ml, a 4Kscore cutoff of 7.5% detected 56% of ISUP grade 2+ cancers with 56% sensitivity and 72% specificity, and would have reduced MRI referrals by 71% and biopsies by 67% versus imaging all men in this PSA range.

  Why it matters: Suggests 4Kscore could help triage men with borderline-low PSA before MRI, though the approach would miss 44% of clinically significant cancers in this range.

• Operator experience did not improve cancer detection with micro-ultrasound in OPTIMUM trial analysis Retrospective · Prostate Cancer Prostatic Dis · 2026-10-31

  A center-level analysis of the multicenter randomized OPTIMUM trial found that operator experience proxies (case volume, mastery score) did not improve discrimination for detecting clinically significant prostate cancer with micro-ultrasound biopsy; AUC was 0.803 regardless of experience level.

  Why it matters: Suggests that enforcing a proficiency threshold (rather than raw volume) before study entry may have minimized learning-curve effects on micro-ultrasound biopsy performance.

• Patterns of imaging progression on Lu-177-PSMA therapy mapped in 361-patient cohort Retrospective · J Nucl Med · 2026-10-30

  In a two-center retrospective review of 361 men on at least two cycles of Lu-177-PSMA therapy, 80% showed shrinking or fewer lesions on serial imaging while 43% eventually progressed, often with new PSMA low-avidity bone lesions.

  Why it matters: Raises the question of how posttreatment imaging patterns, including low-avidity or PSMA-negative progression, could inform monitoring during PSMA radioligand therapy.

• Single-center study links PSMA PET staging to longer survival in localized prostate cancer Retrospective · J Nucl Med · 2026-10-30

  In a retrospective cohort of 6,999 men with localized prostate cancer, the 7.2% who underwent PSMA PET/CT for primary staging had longer time to biochemical recurrence and longer cancer-specific and overall survival after adjustment and propensity matching, with benefit concentrated in high-risk patients treated with radiotherapy.

  Why it matters: Hypothesis generating: selection bias for who received PSMA PET at a single center may not be fully resolved by matching, so this should not be read as proof that PET itself improves survival.

• Fluciclovine PET finds disease in over half of recurrences missed by PSMA PET Prospective · J Nucl Med · 2026-10-30

  In a prospective single-arm study of 50 men with biochemical recurrence and negative PSMA PET, fluciclovine PET/CT was positive in 56% of patients, with detection rising with PSA level, and changed intended management in 71% overall.

  Why it matters: Suggests fluciclovine PET could have a complementary role for localizing recurrence when PSMA PET is negative, though this needs validation against pathologic confirmation in larger cohorts.

• New ASTRO guideline endorses hypofractionated radiation across prostate cancer risk groups Guideline · CancerNetwork · 2026-10-28

  ASTRO has issued an updated guideline supporting use of hypofractionated radiation therapy regimens across risk groups in localized prostate cancer.

  Why it matters: A new society guideline on radiation fractionation could influence treatment planning discussions and referral patterns for localized prostate cancer.

• RCT: Prehabilitation before robotic prostatectomy improves early quality of life and continence RCT · J Urol · 2026-10-29

  In a single-center RCT of 95 men undergoing robotic-assisted radical prostatectomy, a 4-week multimodal prehabilitation program (physical, pelvic floor, nutrition, psychological) improved global quality of life and continence at 1 month. The global quality-of-life benefit attenuated by 6 months, but continence and some other HRQoL and mental health improvements were maintained through 6 months.

  Why it matters: Supports considering structured prehabilitation to improve early recovery and continence after robotic prostatectomy, with sustained continence benefit through 6 months.

• PEACE-1 long-term update: abiraterone added to ADT plus docetaxel extends survival in de novo mCSPC Phase 3 RCT · ecancer · 2026-10-24

  At a median follow-up of 7.7 years, in the 710 men treated with ADT plus docetaxel, adding abiraterone improved overall survival (HR 0.68, 95% CI 0.56 to 0.82; median 6.2 vs 4.4 years). In high-volume disease, median OS was 4.6 vs 3.5 years (HR 0.68) and 38% vs 20% were alive at 8 years. In low-volume disease, median OS was 7.8 vs 6.2 years (HR 0.74, 95% CI 0.52 to 1.05), not significant on its own.

  Why it matters: Strengthens the case for triplet therapy (ADT, docetaxel and abiraterone) in de novo high-volume metastatic castration-sensitive prostate cancer.

Bladder cancer news

• BART phase 3: adjuvant pelvic radiotherapy after cystectomy improves locoregional control in high-risk MIBC Phase 3 RCT · MedPage Today · 2026-10-29

  In 153 patients with high-risk muscle-invasive bladder cancer after radical cystectomy and chemotherapy, adjuvant pelvic radiotherapy improved 2-year locoregional failure-free survival (87.1% vs 76.0%; HR 0.43). Disease-free and overall survival differences were not statistically significant.

  Why it matters: Supports considering adjuvant radiotherapy for selected high-risk patients (e.g., pT3-4 or node-positive disease); without an overall survival benefit, the trade-off is local control against added treatment.

• Review summarizes FGFR alterations as actionable biomarkers across urothelial carcinoma stages Review · JAMA Oncol · 2026-10-30

  This review outlines the biology and clinical applications of FGFR2/3 alterations in urothelial carcinoma, covering genomic profiling, liquid biopsy, and evolving FGFR-targeted therapy strategies across disease stages.

  Why it matters: Offers a practical overview for incorporating FGFR biomarker testing into bladder cancer management as targeted therapies expand.

• KEYNOTE-866: perioperative pembrolizumab with cisplatin-gemcitabine does not improve EFS in cisplatin-eligible MIBC Phase 3 RCT · Urology Times · 2026-10-23

  In 907 cisplatin-eligible patients with MIBC (median follow-up 60.9 months), adding perioperative pembrolizumab to neoadjuvant cisplatin-gemcitabine did not significantly improve event-free survival (HR 0.88, 95% CI 0.71 to 1.10; 60-month EFS 63.5% vs 61.9%). pCR rose to 44.4% vs 35.8%, but OS was identical (HR 1.00). Grade 3 to 5 adverse events were 80.2% vs 75.1%.

  Why it matters: Perioperative pembrolizumab with cisplatin-gemcitabine is not supported for cisplatin-eligible MIBC.

• POTOMAC: durvalumab plus BCG improves DFS in papillary-only, BCG-naive high-risk NMIBC Phase 3 RCT · OncLive · 2026-10-24

  In a prespecified subgroup of 437 patients with papillary-only high-risk NMIBC (median follow-up 60.7 months), durvalumab with BCG induction and maintenance reduced disease-free survival events versus BCG alone (HR 0.56, 95% CI 0.37 to 0.84; 17% vs 30% with events). DFS at 48 months was 84% vs 74%. In the post hoc T1 subset, the HR was 0.48.

  Why it matters: Extends the POTOMAC benefit to papillary-only disease, the largest group of BCG-naive high-risk patients.

• News report: durvalumab plus BCG improved disease-free survival in papillary-only NMIBC News · Urology Times · 2026-10-27

  A news report describes improved disease-free survival with durvalumab added to BCG in BCG-naive, papillary-only NMIBC; underlying trial data are not detailed in this item.

• Adding visugromab to nivolumab raises pathologic complete response in small MIBC trial Phase 1-2 · Nat Med · 2026-10-26

  In the nonrandomized, placebo-controlled phase 2a GDFATHER-NEO trial of 31 cisplatin-ineligible/refusing MIBC patients, neoadjuvant nivolumab plus the GDF-15 antibody visugromab yielded 33% pathologic complete response (5 of 15 evaluable) versus 8% (1 of 13) with nivolumab plus placebo, with no treatment-related delays to surgery.

  Why it matters: Early signal in a small, nonrandomized exploratory trial suggests GDF-15 blockade may enhance neoadjuvant checkpoint inhibition in MIBC, warranting larger randomized confirmation.

• VOLGA: perioperative durvalumab plus enfortumab vedotin improves EFS and OS in cisplatin-ineligible MIBC Phase 3 RCT · N Engl J Med · 2026-10-24

  In 695 patients with MIBC who were cisplatin-ineligible or declined cisplatin (median follow-up 23 months), perioperative durvalumab plus neoadjuvant enfortumab vedotin improved event-free survival versus upfront cystectomy (HR 0.51, 95% CI 0.38 to 0.67; 24-month EFS 64% vs 45%) and overall survival (HR 0.58; 24-month OS 78% vs 69%). pCR was 45% vs 10%. Adding tremelimumab improved EFS (HR 0.61) but not OS at this interim analysis.

  Why it matters: Supports perioperative enfortumab vedotin with checkpoint blockade for patients who cannot receive or decline cisplatin; the FDA has granted the doublet priority review.

Kidney cancer news

• Meta-analysis: 3D reconstruction linked to shorter operative time and fewer complications in partial nephrectomy Meta-analysis · J Endourol · 2026-10-30

  A meta-analysis of 28 studies (3,196 patients) found 3D reconstruction before partial nephrectomy was associated with shorter warm ischemia and operative time, less blood loss, and fewer complications versus standard 2D imaging, with greater benefit in complex tumors, though prediction intervals included the null effect.

  Why it matters: Suggests 3D reconstruction may aid surgical planning for complex renal masses, but wide prediction intervals mean the benefit may not be reproducible across all settings.

• Pan-Asian adaptation of ESMO renal cell carcinoma guidelines published Guideline · UroToday · 2026-10-28

  A pan-Asian adapted version of the ESMO Clinical Practice Guidelines addresses diagnosis, treatment and follow-up for renal cell carcinoma, incorporating regional considerations.

  Why it matters: Provides a regionally adapted reference for RCC management that may differ from Western guideline defaults in drug access and sequencing.

• Intratumoral bacteria linked to myeloid inflammation and progression in kidney cancer (TRACERx Renal) Study · UroToday · 2026-10-28

  A TRACERx Renal study reports that bacteria detected inside kidney tumors are associated with myeloid inflammation and disease progression.

  Why it matters: Raises the question of a tumor microbiome role in RCC biology, though causality and clinical implications remain unclear.

• BMJ review summarizes current standards and gaps in renal cell carcinoma management Review · BMJ · 2026-10-27

  A narrative review covers molecular subtyping, imaging-based diagnosis, surgical options including partial nephrectomy and ablation, adjuvant pembrolizumab for high-risk disease, and checkpoint inhibitor combinations in metastatic RCC, while noting resistance and lack of biomarkers remain challenges.

  Why it matters: Offers a concise overview of the current RCC treatment landscape for clinicians outside subspecialty practice.

• Adding belzutifan or quavonlimab to pembrolizumab-lenvatinib fails to improve PFS or OS in RCC Phase 3 RCT · Ann Oncol · 2026-10-26

  In the phase 3 LITESPARK-012 trial, adding belzutifan or quavonlimab/pembrolizumab to pembrolizumab plus lenvatinib did not improve PFS or OS versus pembrolizumab-lenvatinib alone in first-line advanced clear-cell RCC.

  Why it matters: Confirms pembrolizumab plus lenvatinib remains the standard first-line regimen; these additions did not improve outcomes.

• Belzutifan-lenvatinib keeps PFS and response edge over cabozantinib in RCC, OS not significant Phase 3 RCT · Ann Oncol · 2026-10-26

  Final LITESPARK-011 analysis in previously treated advanced clear-cell RCC shows belzutifan plus lenvatinib maintained PFS (HR 0.74) and response rate benefits over cabozantinib, but mature OS (HR 0.85) did not cross the prespecified significance boundary.

  Why it matters: Supports belzutifan-lenvatinib as an option after anti-PD-(L)1 therapy for PFS and response, though OS benefit remains unproven.

Upper tract urothelial carcinoma news

• Germline testing performed in under 5% of UTUC patients in claims analysis Retrospective · JCO Oncol Pract · 2026-10-31

  A nationwide claims-based analysis of 4,783 patients with newly diagnosed UTUC found only 4.5% underwent germline testing, with no increase from 2015-2023, including just 5.6% of those diagnosed before age 50 who meet guideline criteria.

  Why it matters: Raises the question of whether UTUC care pathways are failing to integrate germline evaluation despite guideline endorsement for Lynch syndrome screening; claims data cannot capture reasons testing was not ordered.

• Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27

  Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.

  Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.

• UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20

  In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.

  Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.

• TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18

  In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).

  Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.

• FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15

  In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).

  Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.

• Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07

  In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.

  Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.

Testicular cancer news

• Testicular cancer incidence concentrated in high-HDI nations, mortality gap widening Study · Urology · 2026-10-28

  GLOBOCAN-based analysis of 185 countries found 72,040 new testicular cancer cases and 9,068 deaths in 2022; incidence correlates with national development level while mortality-to-incidence ratio is far higher in lower-HDI regions, with cases projected to rise 22.7% and deaths 40% by 2050.

  Why it matters: Highlights persistent global disparities in testicular cancer outcomes tied to treatment access rather than disease biology.

• Post-chemo RPLND for seminoma: 84% 5-yr survival in viable seminoma cases, 27% relapsed overall Retrospective · J Urol · 2026-10-08

  Retrospective multi-institutional study of 108 pure seminoma patients undergoing post-chemo RPLND for residual masses. Among those with viable seminoma on pathology, 5-year overall survival was 84%. Overall, 27% of patients relapsed and marker-negative progression independently predicted worse progression-free survival (p<0.001).

  Why it matters: Retrospective data support EAU guidance on centralizing this technically demanding seminoma RPLND procedure, given its morbidity and relapse risk even with favorable survival in viable seminoma cases.

Adrenal tumors news

• Review questions need for universal biochemical workup of adrenal incidentalomas Review · Eur Urol Focus · 2026-11-01

  This review argues that routine biochemical testing for pheochromocytoma may be omitted in homogeneous adrenal masses with 10 Hounsfield units or less on unenhanced CT, per 2023 European Society of Endocrinology guidance, while testing for mild autonomous cortisol secretion remains broadly recommended.

  Why it matters: Offers a risk-stratified framework for adrenal incidentaloma workup that may reduce unnecessary biochemical testing in low-risk imaging phenotypes.

Penile and urethral cancer news

• Phase 2 trial registered: TROP-2 ADC plus PD-1 inhibitor for advanced penile cancer Trial registered · ClinicalTrials.gov · 2026-10-30

  A newly registered single-arm phase 2 trial (SCOPE) plans to evaluate sacituzumab tirumotecan plus toripalimab as chemo-free second-line therapy in platinum-refractory advanced penile squamous cell carcinoma, a setting where current options shrink tumors in only 10-15% of cases. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-01; planned enrollment 31; single site.

  Why it matters: Penile cancer has few second-line options; this trial addresses an unmet need with a TROP-2 targeted ADC combination.

Reconstruction and trauma news

• Retrospective series reports outcomes after revision of difficult-to-catheterize continent channels Retrospective · Neurourol Urodyn · 2026-10-29

  In a single-institution retrospective review of 45 adults undergoing 54 continent catheterizable channel revisions, 76% were free from reoperation at median 46-month follow-up, with success rates similar across suprafascial, subfascial, and replacement techniques.

  Why it matters: Is hypothesis generating for channel revision technique selection given single-center retrospective design without randomized comparison.

• Meta-analysis: PAMORAs linked to faster bowel recovery after radical cystectomy Meta-analysis · Transl Androl Urol · 2026-10-14

  A systematic review and meta-analysis found that adding peripherally acting mu-opioid receptor antagonists (alvimopan, naloxegol, methylnaltrexone) to enhanced recovery pathways after radical cystectomy was associated with shortened time to first flatus and improved postoperative GI recovery versus enhanced recovery alone, though certainty of evidence varied and data specific to cystectomy remain limited and…

  Why it matters: Suggests PAMORAs may help reduce postoperative ileus after cystectomy, but evidence quality is variable and more robust data are needed before routine incorporation into enhanced recovery protocols.

• Systematic review: incisional hernia after robotic prostatectomy varies widely, linked to extraction site Review · Eur Urol Open Sci · 2026-10-12

  Across 16 mostly retrospective studies (56,661 patients), reported incisional hernia after minimally invasive radical prostatectomy ranged from 0.04% to 31%. Two comparative studies found lower rates with Pfannenstiel than periumbilical extraction, and three registry studies reported lower rates after open surgery than after MIRP. Evidence is limited by heterogeneous definitions and follow-up.

  Why it matters: Observational data suggest specimen extraction site and surgical approach may influence incisional hernia risk after robotic prostatectomy, but evidence is heterogeneous and not yet definitive.

• Augmentation cystoplasty shows durable urodynamic benefit over median 19 years in spinal cord injury Retrospective · BJU Int · 2026-10-10

  In a retrospective cohort of 70 patients with spinal cord injury and refractory neurogenic bladder dysfunction, augmentation cystoplasty increased mean bladder capacity from 155 to 490 mL and reduced detrusor pressure from 72 to 19 cmH2O, with continence achieved in 67% over a mean 19-year follow-up; complications included urolithiasis (10%) and malignancy (4%).

  Why it matters: Provides long-term reassurance on durability and complication rates for augmentation cystoplasty in a population with limited surgical alternatives.

Pediatric urology news

• Multidisciplinary review addresses undescended testis management in medically complex children Review · J Urol · 2026-10-29

  A narrative review by specialists across anesthesia, genetics, oncology, and urology examines how standard orchiopexy timing recommendations for undescended testis may need individualized reconsideration in children with syndromic or developmental conditions given elevated surgical risk.

  Why it matters: Offers a framework for weighing surgical and anesthetic risk against fertility and oncologic benefit when managing undescended testis in medically complex children.

• AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16

  The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.

  Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.

• Higher chemotherapy dose and testicular radiation linked to abnormal pubertal hormone patterns in childhood cancer survivors Retrospective · JAMA Netw Open · 2026-10-10

  In a cohort of 221 male childhood cancer survivors, cumulative alkylating chemotherapy dose and testicular radiotherapy above 1 Gy were associated with dose-dependent elevations in pubertal FSH levels, a marker of impaired gonadal function.

  Why it matters: Suggests cumulative alkylator and testicular radiation dose track with gonadal dysfunction, which may help identify survivors for earlier fertility discussions.

Infection, transplant and general urology news

• UNOS data show similar kidney transplant survival in prune belly syndrome versus matched controls Retrospective · Urology · 2026-10-30

  In a propensity-matched UNOS registry analysis of 269 prune belly syndrome kidney transplant recipients versus 1,076 controls, 10-year graft and patient survival did not differ significantly, though confidence intervals were wide.

  Why it matters: Raises the question of whether prune belly syndrome patients can be evaluated for transplant similarly to other candidates, but registry data cannot capture all anatomic or functional nuances of this rare condition.

More urology news

• Phase 3 trial to compare en bloc resection vs standard TURBT for large bladder tumors Trial opening · ClinicalTrials.gov · 2026-10-27

  A new phase 3 trial (planned enrollment 136) will compare pathological and oncological outcomes of modified en bloc resection versus standard transurethral resection for bladder tumors larger than 2.5 cm.

  Why it matters: If positive, could inform technique choice for resection of larger bladder tumors, an area with limited randomized comparative data.

• Ohio urologists saw falling Medicare participation, volume, and pay 2019-2023 Retrospective · Urology · 2026-10-28

  Analysis of CMS data on 411 Ohio urologists found traditional Medicare participation fell 6.1 percentage points, median beneficiaries per provider dropped 15%, and inflation-adjusted payment per beneficiary fell 16% from 2019 to 2023, with similar trends across other surgical specialties.

  Why it matters: Raises questions about Medicare Advantage growth and payment compression effects on urology access, but claims data cannot separate causes.

• Delphi study defines 15 core entrustable professional activities for urology residency graduates Study · Urology · 2026-10-16

  A national Delphi panel of academic urology educators distilled 242 candidate activities into 15 core EPAs that urology residents should perform independently by graduation, covering evaluation, medical management, and a narrower set of procedures.

  Why it matters: Provides a competency-based framework that may inform future resident assessment and milestone evaluation in urology training programs.

• AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06

  Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.

  Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.